Literature DB >> 18193713

Pharmacological management of hypertension.

Bernard Higgins1, Bryan Williams.   

Abstract

Hypertension is a major risk factor for cardiovascular disease, and is both common and amenable to treatment. Several major new studies have appeared recently and in response the National Institute for Health and Clinical Excellence and the British Hypertension Society have collaborated to update their respective guidelines on primary hypertension, and to agree joint recommendations. The update focuses only on pharmacological aspects of treatment. Wherever possible, the recommendations are based on the clinical outcomes of mortality, stroke, myocardial infarction, heart failure, and new onset diabetes mellitus, rather than on blood pressure lowering. A brief treatment algorithm is included. In summary, either calcium channel inhibitors or thiazide-type diuretics should be the preferred initial agent for use in primary hypertension in most patients, although angiotensin converting enzyme (ACE) inhibitors (including angiotensin-II receptor inhibitors if ACE-intolerant) are preferred in patients younger than 55.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18193713      PMCID: PMC4954370          DOI: 10.7861/clinmedicine.7-6-612

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN: 1470-2118            Impact factor:   2.659


  2 in total

1.  Effective systolic blood pressure reduction with olmesartan medoxomil/amlodipine combination therapy: post hoc analysis of data from a randomized, double-blind, parallel-group, multicentre study.

Authors:  Jean-Jacques Mourad; Sylvain Le Jeune
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

Review 2.  Cytochrome P450 and P-Glycoprotein-Mediated Interactions Involving African Herbs Indicated for Common Noncommunicable Diseases.

Authors:  Gregory Ondieki; Makafui Nyagblordzro; Siambi Kikete; Rongjia Liang; Lili Wang; Xin He
Journal:  Evid Based Complement Alternat Med       Date:  2017-01-31       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.